BOSTON and MONTREAL, Nov. 29, 2023 /CNW/ - enGene Holdings Inc. ("enGene,") (NASDAQ:ENGN) (NASDAQ:ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.
Read more at newswire.caenGene Appoints Ryan Daws as Chief Financial Officer
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here